ArticleOncology letters2019
CXCL12 is associated with FoxP3
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Understanding and targeting the tumour matrisome.Nature reviews. Clinical oncology · 2026Review
- FGFR Inhibitor AZD4547 Disrupts Inflammatory CAF Crosstalk With Cancer Cells and Macrophages and Attenuates Metastasis in Pancreatic Cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Review
- Dendrimer Conjugates with PD-L1-Binding Peptides Enhance In Vivo Antitumor Immune Response.Advanced healthcare materials · 2025Article
- Immunoexpression of CXCL12 and CXCR4 in oral tongue squamous cell carcinoma of young and older patients.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Article
- Chemokines and their receptors in oral squamous cell carcinoma: mechanisms, clinical significance, and therapeutic implications.Frontiers in immunology · 2025Review
- Ischemic stroke outcome after promoting CD4+CD25+ Treg cell migration through CCR4 overexpression in a tMCAO animal model.Scientific reports · 2024Article
- Modulating tumoral exosomes and fibroblast phenotype using nanoliposomes augments cancer immunotherapy.Science advances · 2024Article
- Role of tissue markers associated with tumor microenvironment in the progression and immune suppression of oral squamous cell carcinoma.Medical oncology (Northwood, London, England) · 2023Review
- Targeting oral tumor microenvironment for effective therapy.Cancer cell international · 2023Review
- CXCL12 is expressed by skeletal muscle cells in tongue oral squamous cell carcinoma.Cancer medicine · 2023Article
- Cancer-associated mesenchymal stem/stromal cells: role in progression and potential targets for therapeutic approaches.Frontiers in immunology · 2023Review
- Epithelial PD-L1 expression at tumor front predicts overall survival in a cohort of oral squamous cell carcinomas from Sudan.Clinical and experimental dental research · 2022Article
- The Role of Immune Modulatory Cytokines in the Tumor Microenvironments of Head and Neck Squamous Cell Carcinomas.Cancers · 2022Review
- The Protective Role of IL-36/IL-36R Signal in Con A-Induced Acute Hepatitis.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker.Journal of Cancer · 2022Article
- Evaluation of CD4Dental research journal · 2022Article
- Article
- Prognostic Relevance of CD4Biomedicines · 2021Article
- Tenascin-C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression.EMBO molecular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of tumor-infiltrating lymphocytes (TILs) suggests that cancer is a disease with not only a genetic, but also an immunological basis. Additionally, immune cell infiltration is an important feature of oral cancer. C-X-C motif chemokine ligand 12 (CXCL12) serves an important role in immune suppression in the tumor microenvironment. Therefore, the present study investigated how CXCL12 expression in oral squamous cell carcinoma (OSCC) was associated with clinicopathological parameters and TILs distribution. Complete CXCL12, TIL and clinical data were available for 45 patients with oral cancer treated by surgery. Expression levels of CXCL12, CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.